Listing 1 - 4 of 4 |
Sort by
|
Choose an application
Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics.
Epidermal growth factor --- Receptors --- Testing. --- Inhibitors.
Choose an application
Cancer --- Immunotherapy. --- Immunological aspects --- Treatment --- Drug resistance in cancer cells. --- Epidermal growth factor. --- Drug Resistance, Neoplasm --- Epidermal Growth Factor --- Drug Resistance, Neoplasm. --- Epidermal Growth Factor.
Choose an application
The enormity of the literature on growth factors, plus the breadth of the biological disciplines and technical expertise required prohibits a comprehensive review by even a multi-disciplinary panel of authors. To provide an alternative that is feasible for authors and digestible by readers, this review compendium consists of a collection of articles, each covering an aspect of teh ErbB/EGF field. This compilation features articles on growth factor ligands, neuregulins, and individual receptors. The second part of the book concentrates on the biological context of the ErbB receptors, particular
Epidermal growth factor. --- Neoplasms. --- Receptor, Epidermal Growth Factor. --- Tumors. --- Receptors, Growth Factor --- Diseases --- Receptor Protein-Tyrosine Kinases --- Receptors, Gastrointestinal Hormone --- Protein-Tyrosine Kinases --- Receptors, Peptide --- Receptors, Cell Surface --- Protein Kinases --- Membrane Proteins --- Proteins --- Phosphotransferases (Alcohol Group Acceptor) --- Phosphotransferases --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Transferases --- Enzymes --- Enzymes and Coenzymes --- Receptor, Epidermal Growth Factor --- Neoplasms --- Medicine --- Health & Biological Sciences --- Oncology --- Tumors --- Epidermal growth factor --- Growth. --- Receptors. --- Anthelone --- EGF (Growth factor) --- EGF-URO (Growth factor) --- EGF-Urogastrone --- Epidermal growth factor-Urogastrone --- Uroanthelone --- Uroenterone --- Cancer --- Neoplasm growth --- Tumor growth --- Growth --- Growth factors
Choose an application
Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.
Antineoplastic Agents. --- Carcinoma, Non-Small-Cell Lung. --- Genes, erbB-1. --- Anticancer Agents --- Antineoplastic Drugs --- Antineoplastics --- Antitumor Agents --- Antitumor Drugs --- Cancer Chemotherapy Agents --- Cancer Chemotherapy Drugs --- Chemotherapeutic Anticancer Agents --- Chemotherapeutic Anticancer Drug --- Anticancer Agent --- Antineoplastic --- Antineoplastic Agent --- Antineoplastic Drug --- Antitumor Agent --- Antitumor Drug --- Cancer Chemotherapy Agent --- Cancer Chemotherapy Drug --- Agent, Anticancer --- Agent, Antineoplastic --- Agent, Antitumor --- Agent, Cancer Chemotherapy --- Agents, Anticancer --- Agents, Antineoplastic --- Agents, Antitumor --- Agents, Cancer Chemotherapy --- Agents, Chemotherapeutic Anticancer --- Chemotherapy Agent, Cancer --- Chemotherapy Agents, Cancer --- Chemotherapy Drug, Cancer --- Chemotherapy Drugs, Cancer --- Drug, Antineoplastic --- Drug, Antitumor --- Drug, Cancer Chemotherapy --- Drug, Chemotherapeutic Anticancer --- Drugs, Antineoplastic --- Drugs, Antitumor --- Drugs, Cancer Chemotherapy --- Cytotoxins --- Interferon Inducers --- Anticarcinogenic Agents --- Genes, erbB1 --- c-erbB-1 Proto-Oncogenes --- v-erbB Oncogenes --- EGFR Genes --- Epidermal Growth Factor Receptor Genes --- Genes, EGFR --- c-erbB-1 Genes --- erbB-1 Genes --- v-erbB Genes --- EGFR Gene --- Gene, erbB1 --- c erbB 1 Genes --- c erbB 1 Proto Oncogenes --- c-erbB-1 Gene --- c-erbB-1 Proto-Oncogene --- erbB 1 Genes --- erbB-1 Gene --- erbB1 Gene --- erbB1 Genes --- v erbB Genes --- v erbB Oncogenes --- v-erbB Gene --- v-erbB Oncogene --- Nonsmall Cell Lung Cancer --- Carcinoma, Non-Small Cell Lung --- Non-Small Cell Lung Cancer --- Non-Small Cell Lung Carcinoma --- Non-Small-Cell Lung Carcinoma --- Carcinoma, Non Small Cell Lung --- Carcinomas, Non-Small-Cell Lung --- Lung Carcinoma, Non-Small-Cell --- Lung Carcinomas, Non-Small-Cell --- Non Small Cell Lung Carcinoma --- Non-Small-Cell Lung Carcinomas --- Lung Neoplasms --- Carcinoma, Small Cell --- Drug resistance. --- Lungs --- Cancer --- Chemotherapy. --- Resistance to drugs --- Pharmacology --- ErbB Receptors --- Drug Resistance --- ErbB Receptors. --- Lung Neoplasms. --- Drug Resistance.
Listing 1 - 4 of 4 |
Sort by
|